Fate Therapeutics Inc (FATE) 5.91 $FATE Earnings Report

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 2:37 PM

Fate Therapeutics Inc (FATE) 5.91 $FATE

Earnings Report Update: Free Research on Fate Therapeutics, La Jolla,FONAR, TASER, and Allied Motion
PR Newswire - Thu Apr 23, 7:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
FATE: 5.91 (-0.24), FONR: 12.05 (+0.33), LJPC: 22.95 (-1.39), AMOT: 41.04 (+0.49), TASR: 29.67 (-0.01)

Nasdaq stocks posting largest percentage increases
AP - Tue Apr 21, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
TTS: 14.01 (-0.17), FATE: 5.91 (-0.24), HAS: 71.61 (-0.10), ADXS: 23.34 (-0.27), AMSC: 6.88 (-3.12), ECHO: 32.68 (-1.14), LJPC: 22.95 (-1.39), RMBS: 13.99 (-0.31), TGLS: 11.72 (-0.08), VLTC: 11.54 (+0.50), FTNT: 38.68 (-0.04)

Fate Therapeutics (FATE) Jumps: Stock Moves 12.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 8:25AM CDT
Fate Therapeutics (FATE) was a big mover last session, with shares rising over 12% on the day.
BIIB: 401.71 (-28.57), FATE: 5.91 (-0.24)

Fate Therapeutics to Present at 14th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 08, 3:01PM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 12:10 pm EDT in New York, NY.
FATE: 5.91 (-0.24)

Fate Therapeutics to Present at the Regen Med Investor Day
GlobeNewswire - Wed Mar 18, 3:01PM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present at the Alliance for Regenerative Medicine (ARM) 3 Annual Regen Med Investor Day on Wednesday, March 25, 2015 at 11:35 am EDT in New York, NY.
FATE: 5.91 (-0.24)

Leukodystrophies Therapeutics Pipeline Review 2015 - 6 Companies & 6 Drug Profiles
M2 - Wed Mar 18, 7:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m9fmfb/leukodystrophies) has announced the addition of the "Leukodystrophies - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Leukodystrophies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leukodystrophies and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ArmaGen Technologies, Inc. - Fate Therapeutics, Inc. - GlaxoSmithKline plc - Phenomenome Discoveries, Inc. - ReGenX Biosciences, LLC - Shire Plc Drug Profiles - AGT-183 - FT-1050 - Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy - GSK-2696274 - PPI-1011 - SHP-611 For more information visit http://www.researchandmarkets.com/research/m9...ystrophies
FATE: 5.91 (-0.24), SHPG: 255.11 (-0.26), GSK: 46.59 (+0.28)

Fate Therapeutics' (FATE) CEO Dr. Christian Weyer on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 12, 7:07PM CDT

FATE: 5.91 (-0.24)

Fate Therapeutics reports 4Q loss
Automated Insights - Thu Mar 12, 5:22PM CDT
SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Thursday reported a loss of $6.2 million in its fourth quarter.
FATE: 5.91 (-0.24)

Fate Therapeutics beats by $0.01
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 3:19PM CDT

FATE: 5.91 (-0.24)

Fate Therapeutics Reports Year-End 2014 Financial Results
GlobeNewswire - Thu Mar 12, 3:01PM CDT
Favorable Phase 2 Interim Data From Ongoing PUMA Study of PROHEMA(R) in Adult Hematologic Malignancies Reported in December 2014
FATE: 5.91 (-0.24)

Fate Therapeutics Expands and Strengthens Leadership Team
GlobeNewswire - Tue Mar 03, 6:13AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Wendy Levin, M.D., M.S. will join the Company as Vice President, Clinical Development and that Walter Grubb has joined the Company as Vice President, Business Development. Additionally, the Company announced the promotion of John Ferraro to the newly-created position of Vice President, Clinical Operations.
FATE: 5.91 (-0.24)

Recent Developments at Pharma Companies: Special Research on Discovery Labs, Enzon, Fate Therapeutics, Genetic Technologies, and Genocea Biosciences
PR Newswire - Mon Feb 16, 7:20AM CST
Editor Note: For more information about this release, please scroll to bottom.
GENE: 4.70 (-0.13), FATE: 5.91 (-0.24), ENZN: 1.72 (+0.18), GNCA: 12.24 (-0.26), DSCO: 1.24 (-0.02)

Fate Therapeutics to Present at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 3:09PM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 1:50 pm EST in New York, NY.
FATE: 5.91 (-0.24)

Muscular Dystrophy Therapeutic Pipeline Review Research H2 2014 Report Available at RnRMarketResearch.com
PRWeb - Mon Jan 19, 4:31PM CST
The report " Muscular Dystrophy Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Muscular Dystrophy. Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass. In muscular dystrophy, abnormal genes interfere with the production of proteins needed to form healthy muscle. All muscular dystrophies are inherited. Each type of muscular dystrophy is associated with a distinct genetic mutation. The nature of the gene mutation and which chromosome it is located on determine the characteristics of the muscular dystrophy and the way the disease is passed from one generation to the next. The symptoms and age of onset depend on the type of muscular dystrophy. Symptoms of muscular dystrophy often include problems with coordination and mobility with frequent falls, muscle weakness & joint stiffness. Complete Report is Available at http://www.rnrmarketresearch.com/muscular-dys...eport.html .
FATE: 5.91 (-0.24), ISIS: 66.37 (-1.38), SRPT: 13.42 (-0.24)

Fate Therapeutics Announces Key 2015 Objectives for the Advancement of Programmed Cellular Therapeutics Pipeline
GlobeNewswire - Mon Jan 12, 6:07AM CST
Primary Endpoint Read-outs from Adult PUMA and Pediatric PROMPT Studies of PROHEMA in Hematologic Malignancies Expected in mid-2015
FATE: 5.91 (-0.24)

Fate Therapeutics to Present at Biotech Showcase 2015
GlobeNewswire - Tue Jan 06, 6:01AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present an overview of the Company's programs at the 7 Annual Biotech Showcase conference on Monday, January 12, 2015 at 11:30 am PST in San Francisco, CA.
FATE: 5.91 (-0.24)

Will Fate Therapeutics (FATE) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 6:23AM CST
Will Fate Therapeutics (FATE) Continue to Surge Higher?
FATE: 5.91 (-0.24)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 12:05PM CST

FATE: 5.91 (-0.24), SIBC: 21.04 (-0.18), FUR: 16.52 (+0.04), DRAM: 2.28 (unch), NRX: 8.26 (-0.08), MEIL: 1.09 (-0.02), MIG: 8.54 (unch), BCLI: 4.14 (+0.02), ABAC: 1.72 (+0.06), GBR: 2.16 (-0.16), NDRM: 13.61 (-0.14), RCMT: 6.17 (unch), AGRX: 12.77 (+0.33), REN: 1.34 (-0.06), KEG: 2.17 (+0.04), LIME: 2.83 (-0.06), CALA: 13.41 (-0.35), CJJD: 4.01 (+0.27), CBMG: 29.51 (-1.85), GNI: 8.10 (+0.67)

Equities Reward Long-Term Investors: Analyst Notes on Weatherford, ExxonMobil, Ally, UBIC Inc. and Fate Therapeutics
PR Newswire - Mon Dec 22, 8:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Weatherford (NYSE: WFT), ExxonMobil (NYSE: XOM), Ally (NYSE: ALLY), UBIC Inc. (NASDAQ: UBIC), and Fate Therapeutics (NASDAQ: FATE). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
FATE: 5.91 (-0.24), UBIC: 16.31 (-1.05), ALLY: 19.95 (-0.44), WFT: 14.16 (-0.05), XOM: 86.97 (-0.57)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Technical Deep Dive into HONOR X9e Pro's Durability

Rethinking Smartphone Power HONOR's latest device, the X9e Pro, flaunts an 11,000mAh battery—stuck it right behind a neat cover without making the thing feel like a brick. You'd think with a battery that big, they’d have to hire bodybuilders to lift it, but nope. At 8.08mm thick and weighing just 203g, this phone bucks the bulk. They’ve squeezed the power of a power...

Photocure's Q3 2026: Revenue Plateau and CFO Shakeup

The Bladder Cancer Scene: Steady as She Goes Sometimes, you look at numbers and find tranquility, like staring into still waters. That's the scene over at Photocure ASA with their latest Q3 results. Clocking in with revenues of NOK 134.2 million from their Hexvix®/Cysview® products, they're barely flinching from last year's NOK 134.1 million. Is it a victory or a...

Ryde Group Faces Class Action: Key Investor Takeaways

Ryde Group's Tumble: More Than Just Market Volatility When RYDE shares nosedived like a lead balloon, it wasn't due to a market hiccup—it was a darn mess fueled by alleged manipulation. At the heart of this crash are accusations of a blatant pump-and-dump scheme that allegedly swindled investors out of millions. Pump-and-Dump: The Dirty Mechanics This ain't your regular...

Labcorp Lifts 2026 Guidance Amid Strong Q3 Performance

Labcorp's Q3 Numbers Speak Loud and Clear Another quarter, another robust set of numbers for Labcorp (NYSE:LH). The company is strutting into the spotlight with third-quarter 2026 results that have investors nodding in approval. Revenue surged to $3.81 billion, marking a 6.9% increase from the prior year's $3.56 billion. And get this: adjusted EPS jumped 14.5%, clocking...

Clip Expands Horizons with Pulpos Acquisition, New Board Member

Clip's Strategic Move with Pulpos Clip just laid down a serious marker in the digital payment world by snagging Pulpos, a firm that’s got its claws deep into AI-driven business management software. This move isn't just some fancy headline. It's a real, grounded step in expanding Clip's ecosystem to bolster the backbone of Mexico's economy: small and medium-sized...

Beta Bionics: Investors on Edge, Legal Moves Underway

A Tumultuous Time for Beta Bionics Investors Trouble's brewing for those holding Beta Bionics, Inc. (NASDAQ: BBNX) shares. This isn't just market jitters—it's a full-blown legal tussle. The shareholder-rights law honchos at Johnson Fistel are sounding the alarms, and investors better heed their call before the clock strikes November 3, 2026. There's a class action...

BAIC FOTON Builds Service Hub in South Africa

There's something about seeing a company go all-in on a continent like Africa. This time, it's BAIC FOTON, putting down roots in South Africa with a spanking new training center. On October 27, just before their Africa Partners Conference, they opened up the BAIC FOTON Africa Regional Training Center. This move isn't just about bricks and mortar—it's about creating a...

Raleigh's Auction Direct Stresses Oil Changes

Keeping Engines Humming in Raleigh There's nothing quite like keeping an engine running like clockwork, especially in a place like Raleigh where folks rely on their rides day in and day out. That's where Auction Direct USA steps in, offering professional oil change services aimed at preserving the performance and reliability of used cars. A simple yet crucial service:...

Elbit Systems Poised for Q3 2026 Earnings Reveal

Elbit Systems: A Strategic Player in Defense Here's what's going on with Elbit Systems Ltd. (NASDAQ:ESLT), the Israeli defense heavy hitter. They're gearing up to spill the beans on their Q3 financial results this November 17th. And for those of us keeping an eye on how defense contractors are adapting to today's chaotic geopolitical climate, this is a date you don't want...

Quarterra Taps Jeb Cox for Texas Development Leadership

Big Moves in the Lone Star State Jeb Cox is stepping into some rather big cowboy boots over at Quarterra. With nearly two decades under his belt in the multifamily game, he's saddling up as the new Managing Director of Development in Texas. Quarterra, no stranger to the multifamily rodeo, wants to tighten its grip on the bustling Texas market. And Cox, with his gritty,...